Crohn's Disease Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Crohn's Disease market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast

[Nevada, United States] - DelveInsight's "Crohn's Disease Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Crohn's Disease, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Crohn's Disease Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Crohn's Disease Market Report:
• The Crohn's Disease market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Janssen Pharmaceutical K.K. announced a Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
• In October, 2024: AbbVie announced a Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately to Severely Active Crohn's Disease and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy
• In October, 2024: Eli Lilly and Company announced that their Phase 3, Multicenter, Randomized Clinical Study will Evaluate the Mirikizumab in Pediatric Crohn's Disease
• In October, 2024: Merck Sharp & Dohme LLC announced a Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderately to Severely Active Crohn's Disease
• In October, 2024: Takeda announces an open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy With Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn's Disease (CD)
• It is estimated that over 3.1 million people worldwide are affected by Crohn's disease. The disease is most prevalent in North America and Europe, with the United States having a prevalence rate of 214 per 100,000 people.
• Crohn's disease often presents between the ages of 15 and 35, though it can occur at any age. The disease affects men and women almost equally, but some studies suggest a slightly higher prevalence in women.
• In 2023, the total diagnosed prevalent cases of Crohn's Disease in the 7MM were ~1,970,000 cases, which are anticipated to increase during the study period.
• Key Crohn's Disease Companies are as follows: Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast
• Key Crohn's Disease Therapies are as follow: Guselkumab, Upadacitinib, Mirikizumab, Tulisokibart, Vedolizumab, Adalimumab, Ustekinumab, Etrasimod, E6011, Abrilumab, STA-5326, Entocort, CT-P13 SC, MEDI2070
• Launching multiple stage Crohn's Disease pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Crohn's Disease market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Crohn's Disease Overview:
Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract, classified under inflammatory bowel diseases (IBD). It can affect any part of the digestive system, leading to severe complications such as ulcers, strictures, and fistulas. The exact cause of Crohn's is unknown, but it is believed to be a result of genetic predisposition, an overactive immune response, and environmental triggers.

Crohn's Disease Epidemiology Segmentation:
The Crohn's Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Crohn's Disease Total Prevalence
• Crohn's Disease Prevalent Cases by severity
• Crohn's Disease Gender-specific Prevalence
• Crohn's Disease Diagnosed Cases of Episodic and Chronic

For more information about Crohn's Disease companies working in the treatment market, visit https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Crohn's Disease Drugs Uptake
• Adalimumab (Humira): One of the most widely used biologics for moderate to severe Crohn's disease. Its uptake remains strong, although biosimilars like Amjevita and Hulio have entered the market and are gaining traction due to lower costs.
• Infliximab (Remicade): Another anti-TNF biologic with a substantial market share, though its biosimilars (e.g., Inflectra) are capturing significant portions of the market.
• Ustekinumab (Stelara): Approved for moderate to severe Crohn's disease, this interleukin-12 and -23 inhibitor has gained market share due to its favorable safety profile.
• Vedolizumab (Entyvio): An integrin receptor antagonist, Vedolizumab has seen increased uptake, particularly for patients who do not respond to anti-TNF therapy.
• Upadacitinib: A selective JAK1 inhibitor that is undergoing clinical trials, with promising early results.
• Filgotinib: Another JAK1 inhibitor that is progressing through the pipeline and could soon enter the market.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Crohn's Disease Therapies and Key Companies:
• Guselkumab: Janssen Pharmaceutical K.K.
• Upadacitinib: AbbVie
• Mirikizumab: Eli Lilly and Company
• Tulisokibart: Merck Sharp & Dohme LLC
• Vedolizumab, Adalimumab, Ustekinumab: Takeda
• Etrasimod: Pfizer
• E6011: EA Pharma Co., Ltd.
• Abrilumab: Amgen
• STA-5326: Synta Pharmaceuticals Corp.
• Entocort: Padagis LLC
• CT-P13 SC: Celltrion
• MEDI2070: AstraZeneca

Crohn's Disease Epidemiology:
The prevalence of Crohn's disease has been steadily rising over the years, particularly in Western countries, though there are emerging cases in developing nations. It is estimated that over 3.1 million people worldwide are affected by Crohn's disease. The disease is most prevalent in North America and Europe, with the United States having a prevalence rate of 214 per 100,000 people.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Crohn's Disease Market Drivers:
• Increasing Prevalence of IBD
• Advancements in Biologic Therapies:
• Personalized Medicine
• Improved Diagnostic Techniques

Crohn's Disease Market Barriers:
• High Treatment Costs
• Side Effects and Safety Concerns
• Lack of Curative Treatment
• Patient Compliance

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Crohn's Disease Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Crohn's Disease Companies: Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast
• Key Crohn's Disease Therapies: Guselkumab, Upadacitinib, Mirikizumab, Tulisokibart, Vedolizumab, Adalimumab, Ustekinumab, Etrasimod, E6011, Abrilumab, STA-5326, Entocort, CT-P13 SC, MEDI2070
• Crohn's Disease Therapeutic Assessment: Current marketed and emerging therapies
• Crohn's Disease Market Dynamics: Crohn's Disease Market drivers and Crohn's Disease barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Crohn's Disease Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Crohn's Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Crohn's Disease (CD) Market Overview at a Glance
4. Executive Summary of Crohn's Disease (CD)
5. Key Events
6. Disease Background and Overview
7. Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Crohn's Disease (CD): Seven Major Market Analysis
13. KOL Views
14. SWOT Analysis
15. Unmet needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.